| 1 |
Weng L, Zeng XY, Yin P, et al. Sepsis-related mortality in China: a descriptive analysis [J]. Intensive Care Med, 2018, 44(7):1071-1080.
|
| 2 |
Filbin MR, Lynch J, Gillingham TD, et al. Presenting symptoms independently predict mortality in septic shock: importance of a previously unmeasured confounder [J]. Crit Care Med, 2018, 46(10):1592-1599.
|
| 3 |
Parlato M, Philippart F, Rouquette A, et al. Circulating biomarkers may be unable to detect infection at the early phase of sepsis in ICU patients: the CAPTAIN prospective multicenter cohort study [J]. Intensive Care Med, 2018, 44(7):1061-1070.
|
| 4 |
Shankar-Hari M, Datta D, Wilson J, et al. Early prediction of sepsis using leukocyte surface biomarkers: the ExPRES-sepsis cohort study [J]. Intensive Care Med, 2018, 44(11):1836-1848.
|
| 5 |
McHugh L, Seldon TA, Brandon RA, et al. A molecular host response assay to discriminate between sepsis and infection negative systemic inflammation in critically ill patients discovery and validation in independent cohorts [J]. PLoS Med, 2015, 12(12):e1001916.
|
| 6 |
Miller RR 3rd, Lopansri BK, Burke JP, et al. Validation of a host response assay, SeptiCyte LAB, for discriminating sepsis from SIRS in the ICU [J]. Am J Respir Crit Care Med, 2018, 198(7):903-913.
|
| 7 |
Nemati S, Holder A, Razmi F, et al. An interpretable machine learning model for accurate prediction of sepsis in the ICU [J]. Crit Care Med, 2018, 46(4):547-553.
|
| 8 |
Seymour CW, Gesten F, Prescott HC, et al. Time to treatment and mortality during mandated emergency care for sepsis [J]. N Engl J Med, 2017, 376(23):2235-2244
|
| 9 |
Pruinelli L, Westra BL, Yadav P, et al. Delay within the 3-hour Surviving Sepsis Campaign guideline on mortality for patients with severe sepsis and septic shock [J]. Crit Care Med, 2018, 46(4):500-505.
|
| 10 |
Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign bundle: 2018 update [J]. Intensive Care Med, 2018, 44(6):925-928.
|
| 11 |
Komorowski M, Celi LA, Badawi O, et al. The artificial intelligence clinician learns optimal treatment strategies for sepsis in intensive care [J]. Nat Med, 2018, 24(11):1716-1720.
|
| 12 |
Hotchkiss RS, Colston E, Yende S, et al. Immune checkpoint inhibition in sepsis: a phase 1b randomized, placebo-controlled, single ascending dose study of antiprogrammed cell death-ligand 1 (BMS-936559) [J]. Crit Care Med, 2019.doi: 10.1097/CCM.0000000000003685. |